Cargando…
Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement
BACKGROUND: In most jurisdictions, policies have been adopted to encourage the development of treatments for rare or orphan diseases. While successful as assessed against their primary objective, these policies have prompted concerns among payers about the economic burden that might be caused by an...
Autores principales: | Schlander, Michael, Garattini, Silvio, Kolominsky-Rabas, Peter, Nord, Erik, Persson, Ulf, Postma, Maarten, Richardson, Jeff, Simoens, Steven, de Solà-Morales, Oriol, Tolley, Keith, Toumi, Mondher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Co-Action Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087264/ https://www.ncbi.nlm.nih.gov/pubmed/27857828 http://dx.doi.org/10.3402/jmahp.v4.33039 |
Ejemplares similares
-
Determining Value in Health Technology Assessment: Stay the Course or Tack Away?
por: Caro, J. Jaime, et al.
Publicado: (2018) -
Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies
por: Dabbous, Omar, et al.
Publicado: (2022) -
8th European Conference on Rare Diseases & Orphan Products (ECRD 2016): Edinburgh, UK. 26-28 May 2016
por: Schlander, Michael, et al.
Publicado: (2016) -
Health economic evaluation of gene replacement therapies: methodological issues and recommendations
por: Aballéa, Samuel, et al.
Publicado: (2020) -
Personalized Medicine in Screening for Malignant Disease: A Review of Methods and Applications
por: Schmalfuss, F., et al.
Publicado: (2013)